Reports Q2 revenue $31.7M, consensus $16.7M. Cash, cash equivalents and marketable securities as of June 30, 2025 were $366 million compared to $424 million at March 31, 2025. “Our second quarter results reflect revenue acceleration driven by increased investment, strong execution, and growing momentum behind ZURZUVAE, underscoring our collective commitment to advancing care for women with postpartum depression,” said Barry Greene, Chief Executive Officer at Sage Therapeutics (SAGE). “As we work with Supernus to complete the transaction, we take pride in the progress made to date and remain focused on the important work of helping more patients.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Supernus announces expiration of HSR waiting period for Sage Therapeutics
- Sage Therapeutics downgraded to Sector Perform from Outperform at Scotiabank
- Sage Therapeutics cutting over 330 jobs, Boston Globe reports
- Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan
- Avidity, BridgeBio, Coty, SAGE, Alkermes: Trending by Analysts